Extracellular vesicles from human pancreatic islets suppress human islet amyloid polypeptide amyloid formation.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28973954.
- Also identified by DOI 10.1073/pnas.1711389114 and PMC identifier 5651775.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Extracellular vesicles (EVs) are small vesicles released by cells to aid cell-cell communication and tissue homeostasis. Human islet amyloid polypeptide (IAPP) is the major component of amyloid deposits found in pancreatic islets of patients with type 2 diabetes (T2D). IAPP is secreted in conjunction with insulin from pancreatic β cells to regulate glucose metabolism. Here, using a combination of analytical and biophysical methods in vitro, we tested whether EVs isolated from pancreatic islets of healthy patients and patients with T2D modulate IAPP amyloid formation. We discovered that pancreatic EVs from healthy patients reduce IAPP amyloid formation by peptide scavenging, but T2D pancreatic and human serum EVs have no effect. In accordance with these differential effects, the insulin:C-peptide ratio and lipid composition differ between EVs from healthy pancreas and EVs from T2D pancreas and serum. It appears that healthy pancreatic EVs limit IAPP amyloid formation via direct binding as a tissue-specific control mechanism.
Medical subject headings
- Diabetes Mellitus, Type 2
- Extracellular Vesicles
- Islet Amyloid Polypeptide
- Islets of Langerhans
- Plaque, Amyloid